Capital is flowing across many corners of MedTech – with landmark acquisitions, major growth financings, and early bets on emerging technologies. This week’s investor activity points to strong momentum in life-saving devices, AI-enabled platforms, and disruptive delivery systems shaping the future of care.
Terumo to acquire organ preservation device maker OrganOx for $1.5B
Terumo entered into a definitive agreement to acquire OrganOx and its organ preservation technology. The company agreed to acquire all outstanding OrganOx shares for approximately $1.5 billion. Upon completion of the transaction, OrganOx becomes a wholly owned subsidiary of Terumo.
It aims to leverage its MedTech expertise in combination with OrganOx’s advanced capabilities to deliver innovative organ preservation devices globally.
CEO Hikaru Samejima
Last week’s tracker: Iantrek, Luna Diabetes, and more
Tempus to acquire AI digital pathology company Paige
Technology company Tempus AI has announced the acquisition of Paige, a company focused on digital pathology and AI, for a total of $81.25m. The transaction will be settled through Tempus common stock, alongside the assumption of Paige’s existing commitments related to Microsoft Azure cloud services deal.
This acquisition is expected to enhance Tempus’s dataset and expand its technical team.
Founder and CEO Eric Lefkofsky
Restor3d picks up $104m as Partners Group acquires minority stake
Restor3d announced today that it entered into a strategic investment partnership with global private market firm Partners Group. The agreement sees Partners Group acquire a significant minority stake in Restor3d, marking the company’s first institutional investment.
Durham, North Carolina–based Restor3d brought in a total of $104 million through its latest fundraise. That includes $65 million from Partners Group.
CEO Kurt Jacobus
ProVerum secures $80m Series B to advance nitinol stent for BPH
ProVerum Limited, the developer of the ProVee System for BPH, a minimally invasive solution for treating benign prostatic hyperplasia (BPH), announced the closing of an $80 million Series B equity financing.
The financing was led by MVM Partners, who were joined by new investors OrbiMed and the Ireland Strategic Investment Fund (ISIF), and included participation from existing investors Gilde Healthcare Partners, Lightstone Ventures, Atlantic Bridge and Enterprise Ireland amongst others.
CEO Paul Bateman
Vaxxas raises $58.4M for needle-free vaccine delivery tech
Vaxxas announced raised $58.4 million (A$90 million) in a new financing round supporting its vaccine delivery technology. The Brisbane, Australia-based company picked up about $32 million in new Series D equity and about $26 million in debt facilities.
SPRIM Global Investments led the financing, while new investor LGT Crestone also contributed with strong participation. Existing investors One Ventures and Brandon Capital-Hostplus joined in, too.
CEO David Hoey
Twin Health secures $53m to accelerate AI Digital Twin for metabolic health
Twin Health, a company focused on using AI digital twin technology for metabolic health, has announced a $53M investment led by Maj Invest of Denmark.
The new funding will be used to accelerate the company’s expansion among health plans and Fortune 500 clients in retail, healthcare, financial services, technology, and manufacturing.
Founder and CEO Jahangir Mohammed
QT Imaging Receives $5.0 Million in New Funding from Lynrock Lake
QT Imaging Holdings announced that it has received $5.0 million in additional financing via a restated and amended senior secured term loan with Lynrock Lake Master Fund LP.
QT Imaging has used the net proceeds from the transaction to repurchase in full the warrants held by YA II PN, Ltd. (“Yorkville”) as 15,000,000 shares of the Company’s Common Stock at an exercise price of $0.40 per share.
CEO Raluca Dinu
Avasa raises $2.8m pre-Series A for micro-artery coupling device
Avasa completed the first close of its pre-Series A fundraising round worth about $2.8 million (NZD$4.75 million). Movac, one of New Zealand’s largest and longest-standing venture capital funds, led the oversubscribed round. Existing investor Bridgewest Ventures, which led Avasa’s seed round, also participated with several new backers.
The company plans to use funds to support its Avasa Coupler device for reconstructive microsurgery.
Founder and CEO Nandoun Abeysekera
Lumaegis secures early funding for unique sterilisation platform
Lumaegis has closed a pre-seed funding round worth $200,000 to advance its RadBox sterilisation device, which uses a new type of technology not currently on the US medtech market.
It will use the funds obtained from this round to build production units and conduct UL/CE, longevity and FDA-required testing, which the company hopes to initiate later this year.
CEO John Morreale
